$BNTX (-3,32 %) BioNTech - Jeffries upgrades the price target for the 2nd time within a few days. The price target was raised from 96 to 150 dollars. This implies a return potential of over 21% compared to Monday's closing price.
The analyst is modeling risk-adjusted peak sales of 3.6 billion euros for BNT327 and raised his estimate due to the increased conviction regarding the future of the drug.
$BNTX (-3,32 %) Jeffries has raised the price targets for BioNTech today 😀
The share price has suffered recently, but with a weekly balance of +37% and a monthly balance of +47%, it is heading in the right direction again🚀
The target price adjustment reflects the potential that BioNTech's ongoing research and development activities could have for the company's future prospects.
BioNTech's strategy is to prioritize chemotherapy combinations before exploring antibody-drug conjugate (ADC) combinations. To this end, the company has initiated global Phase 2 trials of BNT327 in combination with chemotherapy for breast cancer (BC) and small cell lung cancer (SCLC). In addition, BioNTech plans to complete a first-line study in lung cancer.
Biontech is aiming for first market approval for a cancer drug in 2026, after which annual market approvals in oncology are planned.
$BNTX (-3,32 %) I increased my BioNTech position a little yesterday. Another position went into each of the two children's portfolios.
Certainly a company where you still need a little patience.
In addition to the development of coronavirus vaccines, the focus at Biontech is now on oncology research. The first cancer drug is due to be launched on the market in 2026.
By 2030, the company aims to have achieved ten approvals in various cancer indications.
I've been in here since 2020, at times with over 400% and then back to the starting point 😅. I missed the exit back then and since then I've been keeping my fingers crossed that BioNTech manages to beat cancer. A good share price would then be almost secondary. But so far it remains more of a dream ;)
Bavarian Nordic and BioNTech are two interesting companies in the field of Mpox vaccines. Bavarian Nordic offers the only licensed vaccine (MVA-BN) and is expanding globally to meet the growing demand. BioNTech, on the other hand, is developing an mRNA vaccine that could ensure flexible and rapid production thanks to its technology. $BAVA (+0,92 %) $BNTX (-3,32 %)
Bavarian Nordic has proven products, while BioNTech could convince through innovation. Both companies offer a lot of potential, but which approach is more successful in the long term? What do you think?
The declaration of a global health emergency due to the Mpox virus by the World Health Organization (WHO) gave Bavarian Nordic a boost. The shares of the Danish biotechnology company rose by up to 17 percent and reached 261 kroner, the highest level in almost two years. Bavarian Nordic produces a vaccine against Mpox and announced on Tuesday that the EU agency for crisis preparedness and response HERA had placed an order for vaccine doses to be delivered to Africa. The company also received 156.8 million dollars from the US government to expand its vaccine production.